The Fly

Relay Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer analyst Matthew Biegler initiated coverage of Relay Therapeutics with an Outperform rating and $33 price target. Relay is "one of the most important players in a burgeoning new wave of drug discovery" in the targeted oncology space, said the firm, which believes RLY-4008 looks to be a best-in-class FGFR2 inhibitor.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on RLAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More